Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 19/20 | 0.62 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17286238 | 0.82 | KDM4E (0.54) | TLR8TLR7KDM4ENPSR1L3MBTL1 | |
| SCHEMBL18286678 | 0.81 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL8695685 | 0.79 | TLR8 (0.64) | TLR8TLR7L3MBTL1 | |
| SCHEMBL11752787 | 0.79 | TLR8 (0.73) | TLR8TLR7L3MBTL1 | |
| SCHEMBL19495041 | 0.78 | TLR8 (0.71) | TLR8TLR7 | |
| SCHEMBL17286218 | 0.77 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL20434302 | 0.77 | TLR8 (0.69) | TLR8TLR7L3MBTL1 | |
| SCHEMBL17035544 | 0.76 | TLR8 (0.59) | TLR8TLR7L3MBTL1 | |
| SCHEMBL20434277 | 0.75 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL17693700 | 0.74 | TLR8 (0.57) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903976-B1 | 1,2,4-TRIAZINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS. | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2016-12-07 | — | — | EP | disclosed |
| US-9416114-B2 | 1,2,4-triazine derivatives for the treatment of viral infections | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-16 | — | — | US | disclosed |
| US-20150336907-A1 | 1,2,4-TRIAZINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | UNIVERSITE DE ROUEN (FR) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336907-A1 | 1,2,4-TRIAZINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | MAVS, IL5, ZC3HAV1 | TLR8 177/4885TLR7 51/4885KDM4E 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.